Comerica Bank Purchases 131,715 Shares of Glaukos Co. (NYSE:GKOS)

Comerica Bank grew its position in Glaukos Co. (NYSE:GKOS - Free Report) by 664.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 151,538 shares of the medical instruments supplier's stock after acquiring an additional 131,715 shares during the period. Comerica Bank owned 0.27% of Glaukos worth $22,722,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc acquired a new stake in shares of Glaukos in the fourth quarter valued at $90,000. Picton Mahoney Asset Management bought a new position in shares of Glaukos in the fourth quarter valued at about $125,000. SBI Securities Co. Ltd. bought a new stake in Glaukos during the 4th quarter worth about $153,000. Finally, Smartleaf Asset Management LLC grew its holdings in Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after acquiring an additional 807 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Glaukos Trading Up 0.6 %

GKOS opened at $94.42 on Thursday. The firm's fifty day moving average is $99.10 and its two-hundred day moving average is $129.41. The firm has a market cap of $5.39 billion, a PE ratio of -32.90 and a beta of 0.88. Glaukos Co. has a twelve month low of $77.91 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same quarter last year, the business posted ($0.70) EPS. The firm's revenue was up 24.6% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Truist Financial reduced their target price on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC upped their price objective on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Wells Fargo & Company lifted their target price on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Mizuho cut their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 16th. Finally, Piper Sandler decreased their price target on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus target price of $156.17.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.